Palisade Bio, Inc. (NASDAQ: PALI) reported a net loss of $10.6 million for the second quarter ended June 30, 2026, widening significantly from the $2.8 million net loss in the same period of 2025. The clinical-stage biopharmaceutical company attributed the higher burn rate to accelerated research and development activities for its lead candidate, PALI-2108. Despite the widened loss, the company maintains a strong balance sheet with $125.2 million in cash and cash equivalents, sufficient to fund operations through key Phase 2 clinical readouts expected in late 2027 and early 2028. The quarterly earnings per share (EPS) of $(0.05) met analyst consensus estimates, reflecting market expectations for the increased investment phase.

The financial performance reflects the company’s transition into more advanced clinical development stages. Research and development expenses rose to $7.4 million in Q2 2026 from $1.7 million in Q2 2025. This increase was primarily due to higher employee-related costs, including non-cash stock-based compensation, and expanded program expenses for chemistry, manufacturing, and controls (CMC) activities. General and administrative expenses also climbed to $4.8 million from $1.2 million year-over-year, driven by professional fees and personnel costs associated with organizational growth. Partially offsetting these operating losses, Palisade Bio recognized $0.5 million in license revenue from a milestone achievement under a co-development agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited.

Clinical Development Progress

The increased investment supports the advancement of PALI-2108, a once-daily oral PDE4 inhibitor prodrug engineered for targeted activation in the gastrointestinal tract. The company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase 2 ASCENTRA-UC trial targeting ulcerative colitis. Enrollment of the first patient is expected in the second half of 2026, with primary efficacy results anticipated in the second half of 2027. Additionally, Palisade Bio plans to submit an IND application for the Phase 2 ASCENTRA-CD trial for Crohn’s disease in the second half of 2026, with trial commencement targeted for the first quarter of 2027 and primary readouts expected in early 2028.

These developments build on encouraging data from the completed Phase 1 clinical trial. In the ulcerative colitis cohort, all five patients achieved clinical response, with two achieving remission based on the Modified Mayo Score. In the fibrostenotic Crohn’s disease cohort, PALI-2108 reduced the mean SES-CD score by approximately 47.5%, with two out of five patients achieving both endoscopic response and remission. JD Finley, Chief Executive Officer, noted that the quarter marked a decisive transition as the company completed regulatory and operational work required to advance PALI-2108 into Phase 2 development.

Financial Highlights

The following table summarizes Palisade Bio’s key financial metrics for the three months ended June 30, 2026, compared to the same period in 2025. All figures are in thousands of U.S. dollars.

Cash and cash equivalents stood at $125,172 thousand as of June 30, 2026, down from $133,385 thousand at the end of fiscal year 2025. The company also reported $500 thousand in accounts receivable, primarily related to the license milestone payment. Total assets decreased slightly to $127,315 thousand from $134,344 thousand year-end 2025, while total liabilities rose modestly to $5,567 thousand from $4,964 thousand.

What the Numbers Show

A notable divergence exists between the widening absolute net loss and the improving per-share loss metric. While the total net loss increased by approximately 280% year-over-year, the net loss per share improved significantly from $0.58 to $0.05. This improvement is driven by a substantial increase in weighted average shares outstanding, which rose from 4.8 million in Q2 2025 to 211.4 million in Q2 2026. This share count expansion likely reflects capital raising activities or warrant exercises during the interim period, diluting existing shareholders but spreading the operational losses across a larger equity base. Investors should monitor whether this increased capitalization aligns with the extended cash runway provided by the current liquidity position.

Palisade Bio, Inc. will engage with institutional investors at the Leerink Partners Therapeutics Forum in Boston on July 14-15, 2026, to outline its clinical development strategy and recent progress with its lead asset, PALI-2108. The company's management, including Chief Executive Officer JD Finley and President & Chief Medical Officer Dr. Mitchell Jones, will conduct one-on-one meetings throughout the conference. These discussions will focus on the advancement of PALI-2108 and upcoming milestones across the company's inflammatory bowel disease programs.

Clinical Development Strategy

The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon. This mechanism aims to initiate targeted PDE4 inhibition at disease sites while enabling systemic distribution of the active drug. Palisade Bio reported that PALI-2108 has demonstrated encouraging results in Phase 1 studies, which included trials involving ulcerative colitis and fibrostenotic Crohn’s disease.

Upcoming Milestones

Palisade Bio is currently preparing for Phase 2 clinical studies in ulcerative colitis and Crohn’s disease. The company's precision pharmacology strategy is centered on transforming proven PDE4 biology into improved oral therapies for patients with chronic inflammatory and fibrotic diseases. The investor meetings at the forum will provide a platform to detail the timeline and objectives for these upcoming trials.

Conference Details

The company's platform focuses on improving pharmacology, tolerability, and convenience for patients suffering from these conditions. Further information about the company's pipeline is available on its official website.